 |
|
|
|
Accounting for FDAAA, clinicaltrials.gov and ICMJE
Critical concerns for drugs, biologics and devices
October 5, 2009
1:30 p.m. ET
90 minutes
Part 4 of a 4-part series: Evolving Issues in Publication Planning: Smart Strategies for Success
This 90-minute webinar explores the long list of requirements from each of these entities – and what these requirements mean for those under the “pharmaceutical umbrella.” From timeline challenges to varying trial procedures, manufacturers of drugs, biologics and medical devices face specific challenges. Demystify this regulatory maze! Topic experts address:
- Its all about timing: A comprehensive breakdown of disclosure requirements
- What are the differences in requirements for drugs, biologics and devices?
- Taking varying trial procedures into account: Red flags to watch for
- Coordinating with your colleagues and management for a smooth disclosure process
Presenters:
Keith Veitch, Head of Global Publications, Novartis Vaccines
Mark Molenda, Associate Director, Medical Affairs Strategic Trials Team, Centocor Ortho-Biotech Services LLC
Scott Lassman, Partner, Kleinfeld, Kaplan and Becker LLP
Jane Moore, Principal Publications Specialist, Medtronic
Register Today!
Individual Registration - $395
Any subsequent registrations will receive a 15% discount.
*Group Registration Options - $1,995
Access for 45 or fewer attendees from the same company. For group registrations of 45 or more, please contact Kathie Eberhard at 704-341-2439 or keberhard@frallc.com.
*Please note when registering delegates under Group Registrations you must submit an advance list of attendees from your organization including email address and name.
|
|
|
|